Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.57 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.56 |
| ▸ | CYTH2 | Q99418 | 1/20 | 0.54 |
| ▸ | NMT1 | P30419 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18903978 | 0.89 | LMNA (0.64) | LMNAHTTSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL16509593 | 0.87 | LMNA (0.61) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502976 | 0.86 | LMNA (0.63) | LMNAHTTSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL16502944 | 0.83 | SMN1; SMN2 (0.64) | LMNAHTTSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL16502992 | 0.83 | LMNA (0.71) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16817058 | 0.83 | LMNA (0.71) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16509495 | 0.82 | FFAR4 (0.60) | LMNAHTTSMN1; SMN2L3MBTL1FFAR4 | |
| SCHEMBL16502936 | 0.81 | SMN1; SMN2 (0.68) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 | |
| SCHEMBL16502937 | 0.80 | KMT2A (0.57) | LMNASMN1; SMN2L3MBTL1NMT1ALDH1A1 | |
| SCHEMBL16502943 | 0.80 | KMT2A (0.59) | LMNAHTTSMN1; SMN2L3MBTL1NMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828346-B2 | N-myristoyl transferase inhibitors | UNIVERSITY OF DUNDEE (GB) | 2017-11-28 | — | — | US | disclosed |
| EP-2980076-B1 | Pyrazolyl derivatives | UNIV DUNDEE (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-20160060224-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIVERSITY OF DUNDEE (GB) | 2016-03-03 | — | — | US | disclosed |
| EP-2980076-A1 | PYRAZOLYL DERIVATIVES | University of Dundee (GB) | 2016-02-03 | — | — | EP | disclosed |
| US-9156811-B2 | N-myristoyl transferase inhibitors | Univeristy of Dundee (GB) | 2015-10-13 | — | — | US | disclosed |
| US-20110312921-A1 | N-Myristoyl Transferase Inhibitors | DUNDEE, UNIVERSITY OF (GB) | 2011-12-22 | — | — | US | disclosed |
| WO-2010026365-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | UNIVERSITY OF DUNDEE (GB) | 2010-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312921-A1 | N-Myristoyl Transferase Inhibitors | GNMT, NNMT, SPTLC1 | LMNA 4097/4885HTT 1540/4885SMN1; SMN2 3634/4885 |
| US-20160060224-A1 | N-MYRISTOYL TRANSFERASE INHIBITORS | GNMT, NNMT, SPTLC1 | LMNA 4097/4885HTT 1540/4885SMN1; SMN2 3634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.